SUBSCRIBE
SUBSCRIBE
News   Drug Development

Roche Holding AG, Biogen Idec, Inc. (Massachusetts) Suspends Arthritis Treatment Ocrelizumab After Deaths

March 8, 2010 | 
1 min read

Reuters -- Swiss drugmaker Roche Holding AG (ROG.VX) and U.S.-listed Biogen Idec (BIIB.O) are suspending rheumatoid arthritis and lupus treatment ocrelizumab after it caused deaths, casting doubt over the drug’s future.

Clinical research Phase III
Biogen
MORE ON THIS TOPIC
Beautiful colorful unpeeled peanut pattern on a light blue background. Flat lay arrangement, top view.
Immunology and inflammation
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Human Nose Like Worker Is Going To Work. Vector Collage Illustration Against The Background Of The City
Immunology and inflammation
AstraZeneca, Amgen’s Phase III Win Strengthens Case for Tezspire Expansion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
3D illustration of an RNA molecule
Cardiovascular disease
Silence Quiets Phase III Pace for Lipoprotein Drug, Seeks Partner
February 28, 2025
 · 
2 min read
 · 
Tristan Manalac
mRNA leaves the nucleus, it moves to a ribosome 3d rendering
Opinion
How mRNA Can Help Bridge the Innovation Gap in Rare Disease
February 28, 2025
 · 
3 min read
 · 
Kyle Holen